Theralase Anti-Cancer Technology

NEWS ALERT: We are pleased to announce that Carolina Urologic Research Center has received site Institutional Review Board approval to commence a Pivotal Phase II Non-Muscle Invasive Bladder Cancer Clinical Study. This marks the fourth US clinical study site that has obtained site IRB approval through a central IRB. Read more: https://theralase.com/theralase-launches-fourth-clinical-s/... #theralase #theralasenews #cancerresearch #bladdercancer #nmibc #clinicaltrials #phase2 #clinicalstudy

STUDY II UPDATE: We are pleased to announce that MidLantic Urology has received Institutional Review Board approval to commence a Phase II Non-Muscle Invasive Bladder Cancer Clinical Study. Read More: https://theralase.com/theralase-launches-third-clinical-st/ #theralase #theralasenews #cancerresearch #bladdercancer #nmibc #clinicaltrials #phase2 #clinicalstudy

STUDY II UPDATE: Urology Associates has become the second US study site to receive Institutional Review Board approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer Clinical Study. Read more: https://theralase.com/theralase-launches-second-clinical-s/ #theralasetechnologies #theralase #nmibc #cancer #oncology #clinicaltrials #bladdercancer

STUDY II UPDATE: We are thrilled to announce that Virginia Urology has received site Institutional Review Board approval to commence a pivotal phase II NMIBC Clinical Study, leading this to be the first US Clinical Study Site. Read more: https://theralase.com/theralase-launches-first-clinical-st/ #clinicalresearch #oncology #theralase #tlt #nmibc #cancerresearch #clinicaltrials

STUDY 2 UPDATE: The University of British Columbia Review Ethics Board has approved the commencement of a Pivotal Phase II Non-Muscle Invasive Bladder Cancer Clinical Study. Read more: https://theralase.com/university-of-british-columbia-launc/ #theralase #bladdercancer #nmibc #clinicalstudy #oncology #cancer

Don't miss out! Theralase Technologies Inc. will be presenting at 11:20 AM EST on December 15, 2020 at the LD Micro Main Event (XIII). Join the event: https://bit.ly/2WgHnve

STUDY 2 UPDATE: Theralase Granted FDA Fast Track Designation for NMIBC Phase II Clinical Study. Read more: https://theralase.com/theralase-granted-fda-fast-track-des/... #theralase #bladdercancer #nmibc #cancer #research #fta

NEWS ALERT: Theralase Technologies (TSXV: TLT) announced today that its PDC technology has demonstrated a high kill rate in a #preclinical analysis of #coronavirus, Biological Safety Level (BSL-2). Read more in the link below. #covid19 #research #theralase #pdt #coronavirusupdate #covidupdate #covidvaccine #vaccine... https://theralase.com/theralase-technology-demonstrates-hi/

NEWS ALERT: Theralase Technologies (TSXV: TLT) has executed a Sponsored Research Agreement (SRA) with the University of Manitoba (UM) Medical Microbiology department to commence the development of a #coronavirus vaccine and therapy utilizing Theralase’s patented and proprietary PDCs. Learn more in the link below. https://theralase.com//theralase-signs-agreement-with-uni/... #theralase #TheralaseTechnologies #tlt #covid19 #coronavirusnews #research #biotechnology

Theralase Technologies (TSXV: TLT) is pleased to present the Q2 Quarterly Newsletter. The Newsletter provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study. Read more: https://bit.ly/2FpetUu... If you would like to receive Theralase news and updates directly to your inbox, please email us at [email protected] #theralase #TheralaseTechnologies #cancerresearch #NMIBC #biotech #anticancer

Theralase Technologies (TSXV: TLT) is pleased to present the Q2 Quarterly Newsletter. The Newsletter provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study. Read more: https://bit.ly/2FpetUu... If you would like to receive Theralase news and updates directly to your inbox, please email us at [email protected] #theralase #TheralaseTechnologies #cancerresearch #NMIBC #biotech #anticancer

Theralase Technologies is recognized as a top performer in the Clean Technology & Life Sciences sector and is proud to be named a 2020 Venture 50 Company. With the recent FDA IND authorization, Theralase TechnologiesTheralase Anti-Cancer Technology is excited to advance the novel Anti-Cancer Technology platform in the USA. #TSXV50

The current standard of care for Non-muscle Invasive Bladder Cancer (NMIBC) is a Trans-Urethral Resection of the Bladder Tumour (TURBT) followed by a series of treatments with a vaccine called Bacillus Calmette Guerin (BCG). Approximately 30% of patients will become unresponsive to this vaccine, in which case, a Radical Cystectomy is the next recommended option by most healthcare providers. Radical Cystectomy is the surgical removal of the bladder (and adjacent or...gans) which many patients may be unfit for, or desire a treatment option that allows them to preserve their bladder. Theralase Technologies is investigating a potential treatment of BCG-Unresponsive NMIBC that has shown a 67% response rate during a clinical trial treating a small number of patients. Visit our website to learn more about #TheralaseTechnologies. #CancerDevelopment #CancerResearch

Massive Congratulations to Dr. Wassim Kassouf, Theralase's Principle Investigator at Centre universitaire de santé McGill | McGill University Health Centre #bladdercanceraware

Heartfelt words of support from Bladder Cancer Canada Co-founder, Jack Moon. Thank you to everyone who has continuously supported Theralase in the development of the Anti-Cancer treatment for Non-Muscle Invasive Bladder Cancer. Read more at https://theralase.com//theralase-receives-fda-ind-authori/ #BladderCancerAware #BladderCancerAwarenessMonth Bladder Cancer Canada / Cancer de la vessie Canada

DID YOU KNOW? Bladder cancer is the most common malignancy involving the urinary system and there are 3 different types: non-muscle invasive, muscle invasive, and metastatic disease. Approximately 70% of all new cases are classified as Non-Muscle Invasive Bladder Cancer. ##bladdercancerawareness #bladdercanceraware

NEWS ALERT: #TheralaseTechnologies has received FDA Investigational New Drug authorization to conduct a Phase II Non-Muscle Invasive #BladderCancer clinical study in the United States. Learn more in the link below https://theralase.com//theralase-receives-fda-ind-authori/ #FDA #NMIBC #CancerDevelopment #cancerawareness #Bladdercanceraware #Bladdercancerawarenessmonth ... #clinicalstudies #USA #PDT #MovingMetals See more

See red? Be sure to talk to a healthcare provider. Blood in the urine is the most common sign of bladder cancer. It's #BladderCancerAwarenessMonth and like any disease, it is important to understand the signs, symptoms and risks involved. Visit https://theralase.com/bladder-cancer-awareness-month/ to learn more. #BladderCancerAware

Happy #InternationalNursesDay! We want to take a moment to share our sincerest gratitude for all the nurses that have been working tirelessly and putting their own livelihood at risk to keep us healthy during this global pandemic. Thank you today and every day for keeping our loved ones safe! The work you do for our community is priceless. #NursesWeek2020

Due to the high reoccurrence rate with the treatment methods that are currently available, Bladder Cancer is the most costly cancer to treat over a patients lifetime. Visit https://theralase.com/bladder-cancer-awareness-month/ to learn more and be #bladdercanceraware Reference: Santos, F., Dragomir, A., Zakaria, A.S. et al. Health-care services utilization and costs associated with radical cystectomy for bladder cancer: a descriptive population-based study in the province of Quebec, Canada. BMC Health Serv Res 15, 308 (2015). https://doi.org/10.1186/s12913-015-0972-3

#BladderCancerAwarenessMonth is here and like any disease, it is important to understand the signs, symptoms & risks. Visit https://theralase.com/bladder-cancer-awareness-month/ to learn more and be #BladderCancerAware

#SocialDistancing doesn't mean you can't be social! Follow Theralase on Twitter, Instagram and LinkedIn #StaySafeStayHome #Theralase #Theralasetech #AntiCancerTech #BladderCancer

#Theralase provides Company update on Phase II Non-Muscle Invasive #BladderCancer clinical study. See link below #Theralasetech #Technology #AntiCancer #NMIBC #PDT

Bladder Cancer Canada released its March newsletter, covering #COVID19, a #BCG shortage update, inspiring patient stories and more! Check out the link below for updates surrounding #bladdercancer